You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Abbott has terminated its prior $5 billion credit agreement also with JP Morgan reached in November 2018.
The firm's variety of COVID-19 molecular and immunoassay test offerings offset declines in the point-of-care segment.
A small study has found that a rapid test for SARS-CoV-2 works about as well as a PCR test, according to the New York Times.
The company has shipped more than 12 million ID Now tests across the US and more than 30 million total COVID-19 tests since March.
About 150 million rapid coronavirus tests purchased by the US federal government are to be distributed to nursing homes, colleges, and the states, according to the New York Times.
The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.
One of the revisions specifies that the ID Now test is for use with specimens collected within the first week of symptom onset.
Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.
While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.
The US Food and Drug Administration has issued an Emergency Use Authorization for Abbott's antigen test for SARS-CoV-2.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.